The Myelodysplastic Syndromes (MDS) Foundation
The Myelodysplastic Syndromes (MDS) Foundation was created by a group of international physicians and researchers who wanted to make sure that information about MDS was always available. Now, the organization has developed to include patient advocacy groups, research funding, and educational initiatives. In addition, the MDS Foundation works to set up an international information network to contact patients for available clinical trials, thus sharing new treatment options in the community.
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Resources & Support
Patient Worthy Posts on Myelodysplastic syndromes
First Patient Treated in NKX101 Trial for AML, MDS
Recently, biopharmaceutical company Nkarta announced the dosing of the first patient in its Phase 1 clinical trial. Within the trial, researchers will evaluate and
Presentations Demonstrate Promising Advances in Blood Cancers and Blood Disorders
According to a story from PR Newswire, presentations at the 60th annual American Society of Hematology Meeting and Exposition are highlighting the results of four
Phase 3 Myelodysplastic Syndromes Trial Reaches Enrollment Milestone
According to a story from sectorpublishingintelligence.co.uk, the biopharmaceutical company Onconova Therapeutics, Inc. recently announced that they have successfully surpassed the 75 percent milestone for enrollment
You Won’t Feel Sad With MDS When You Have These 3 Things
While his peers were getting learners’ permits and homecoming tickets, 16-year-old Conner Vollmer was getting an unexpected diagnosis of myelodysplastic syndrome (MDS). The pre-cancerous condition
Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia May Increase with PARP Inhibitors
Poly (ADP-Ribose) polymerase inhibitors (PARP inhibitors) are used to treat neoplasms. They are frequently used as a therapy for ovarian cancer. A recent study has
.jpg)
A Look at Progress in Healthcare and a Glimpse into the Future
The Asco Post recently interviewed Dr. Jean Pierre Bizzari, the Executive Vice President of Celgene, a multinational bioparmaceutical company. The interview covered various aspects
